PMV Pharmaceuticals, Inc. (PMVP): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo de vanguardia de la oncología de precisión, PMV Pharmaceuticals surge como un innovador innovador dirigido al escurridizo panorama de mutaciones p53. Al aprovechar el diseño avanzado de medicamentos computacionales y una plataforma tecnológica patentada, esta compañía de biotecnología está revolucionando el tratamiento del cáncer a través de estrategias terapéuticas altamente específicas. Su enfoque único promete desbloquear posibles terapias para cánceres previamente no tratables, posicionando los productos farmacéuticos de PMV a la vanguardia de la medicina personalizada y ofreciendo esperanza a pacientes con mutaciones genéticas complejas que han desafiado durante mucho tiempo las intervenciones oncológicas tradicionales.

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negocio: asociaciones clave

Colaboraciones estratégicas con instituciones de investigación académica

PMV Pharmaceuticals ha establecido asociaciones críticas de investigación con las siguientes instituciones académicas:

Institución	Enfoque de colaboración	Año iniciado
Universidad de Pensilvania	investigación de mutación p53	2019
Universidad de Johns Hopkins	Estudios de oncología de precisión	2020

Asociaciones de desarrollo farmacéutico con organizaciones de investigación por contrato

PMV Pharmaceuticals colabora con organizaciones de investigación de contratos especializadas (CRO) para el desarrollo de medicamentos:

• IQVIA - Gestión de ensayos clínicos
• Parexel International - Apoyo de investigación preclínica
• Medpace - Diseño de ensayo clínico de oncología

Posibles acuerdos de licencia

Las posibles asociaciones de licencias farmacéuticas incluyen:

Compañía farmacéutica	Área de colaboración potencial	Estado
Merck & Co.	P53 terapias dirigidas	Discusiones exploratorias
Bristol Myers Squibb	Tratamientos de oncología de precisión	Negociaciones preliminares

Colaboraciones de investigación en oncología de precisión

Asociaciones de investigación de oncología de precisión actual:

• Memorial Sloan Kettering Cancer Center - Perfil molecular
• Dana -Farber Cancer Institute - Desarrollo de terapia dirigida
• MD Anderson Cancer Center - Investigación genómica

Inversión total de asociación de investigación: $ 12.4 millones en 2023

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negocio: actividades clave

P53 dirigió a la investigación y el desarrollo de los medicamentos contra el cáncer

A partir del cuarto trimestre de 2023, PMV Pharmaceuticals se centró en desarrollar terapias dirigidas P53 con un presupuesto de investigación específico de $ 54.3 millones dedicado a la investigación y el desarrollo oncológicos.

Enfoque de investigación	Inversión	Indicación objetivo
Terapias específicas de mutación p53	$ 28.7 millones	Tumores sólidos avanzados
Nuevas plataformas de oncología de precisión	$ 25.6 millones	Tratamientos de cáncer dirigidos

Modelado molecular y diseño de fármacos computacionales

PMV utiliza plataformas computacionales avanzadas con una inversión tecnológica anual de $ 12.5 millones en infraestructura de modelado molecular.

• Algoritmos avanzados de aprendizaje automático para el modelado de interacción de proteínas
• Sistemas informáticos de alto rendimiento
• Herramientas computacionales de biología estructural patentada

Gestión y ejecución del ensayo clínico

Presupuesto de desarrollo clínico para 2024: $ 67.2 millones, apoyando múltiples ensayos clínicos en curso en diferentes indicaciones oncológicas.

Estadio clínico	Número de pruebas activas	Objetivo de inscripción de pacientes
Fase 1	3 pruebas	180 pacientes
Fase 2	2 pruebas	250 pacientes

Procesos de presentación y cumplimiento reglamentarios

Presupuesto de asuntos regulatorios: $ 8.3 millones, con un equipo dedicado de 12 especialistas regulatorios que administran interacciones de la FDA y EMA.

Desarrollo terapéutico de oncología de precisión innovadora

Inversión en I + D en plataformas de oncología de precisión: $ 41.9 millones, dirigidos a mutaciones genéticas específicas en tratamientos contra el cáncer.

• Enfoque terapéutico personalizado
• Diseño de fármacos específicos de mutación
• Estrategias de tratamiento basadas en biomarcadores

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negocio: recursos clave

Plataforma de tecnología de orientación de mutación p53 patentada

PMV Pharmaceuticals ha desarrollado una plataforma de tecnología especializada centrada en dirigirse a mutaciones específicas de cáncer p53. A partir del cuarto trimestre de 2023, la compañía ha identificado y caracterizado a más de 30 objetivos de mutación p53 únicos para posibles intervenciones terapéuticas.

Métricas de plataforma tecnológica	Datos cuantitativos
Objetivos de mutación p53 únicos	Más de 30 mutaciones identificadas
Inversión de investigación	$ 12.5 millones asignados en 2023
Solicitudes de patentes	8 Presentaciones de patentes activas

Equipo de investigación científica especializada

La compañía mantiene un sólido equipo científico con experiencia oncológica profunda.

• Personal de investigación total: 65 empleados
• Investigadores de doctorado: 42
• Áreas de especialización: oncología, biología computacional, genética molecular

Infraestructura avanzada de descubrimiento de fármacos computacionales

Capacidades computacionales: PMV utiliza sistemas informáticos de alto rendimiento para modelado molecular y descubrimiento de fármacos.

Componente de infraestructura	Especificación
Potencia de procesamiento computacional	512 teraflops
Capacidad de almacenamiento de datos	2.5 petabytes
Algoritmos de aprendizaje automático	17 algoritmos desarrollados a medida

Cartera de propiedades intelectuales

PMV Pharmaceuticals mantiene una estrategia de propiedad intelectual robusta para la nueva terapéutica del cáncer.

• Patentes activas totales: 12
• Familias de patentes: 5
• Cobertura geográfica: Estados Unidos, Europa, Japón

Financiación de la investigación y el desarrollo

Las fuentes de financiación respaldan iniciativas continuas de investigación y desarrollo.

Fuente de financiación	Cantidad (2023)
Inversiones de capital de riesgo	$ 45.3 millones
Subvenciones del gobierno	$ 7.2 millones
Colaboraciones de investigación	$ 3.5 millones

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negocio: propuestas de valor

Terapéutica oncológica de precisión dirigida a mutaciones p53 específicas

PMV Pharmaceuticals se centra en el desarrollo de terapias de cáncer dirigidas que aborden específicamente las mutaciones del gen p53. A partir del cuarto trimestre de 2023, la compañía tenía 3 candidatos a medicamentos principales en el desarrollo clínico dirigido a mutaciones p53 específicas.

Candidato a la droga	Tipo de mutación	Estadio clínico	Tipos de cáncer objetivo
PC14586	Mutación P53 Y220C	Fase 1/2	Tumores sólidos
PC577	P53 R273 Mutación	Preclínico	Múltiples tipos de cáncer

Enfoque innovador para el tratamiento del cáncer

El enfoque de medicina de precisión de PMV se dirige a alteraciones moleculares específicas en las células cancerosas. La valoración del mercado de la compañía a enero de 2024 era de aproximadamente $ 425 millones.

Potencial para desarrollar terapias para cánceres previamente no tratables

• Población de pacientes direccionable estimada para mutaciones p53: aproximadamente 50,000 pacientes anualmente
• Tamaño del mercado potencial para la precisión P53 Terapias: más de $ 1.2 mil millones
• Focalización única de mutaciones p53 previamente 'indioscables'

Metodología avanzada de diseño de medicamentos computacionales

PMV utiliza plataformas computacionales patentadas para el descubrimiento de fármacos. Los gastos de investigación y desarrollo en 2023 fueron de $ 86.3 millones, lo que representa un aumento del 22% de 2022.

Terapias dirigidas con potencial para mejorar los resultados del paciente

Métrico	Valor
Inversión de I + D	$ 86.3 millones (2023)
Inversiones de ensayos clínicos	$ 42.7 millones (2023)
Cartera de patentes	23 patentes otorgadas

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negocio: relaciones con los clientes

Comunidad directa de compromiso con la investigación de oncología

PMV Pharmaceuticals mantiene la participación directa a través de interacciones específicas con investigadores e instituciones clave de oncología. A partir del cuarto trimestre de 2023, la compañía reportó 87 colaboraciones de investigación directa con centros de investigación académica y médica.

Tipo de compromiso	Número de interacciones
Asociaciones de investigación académica	42
Colaboraciones del Centro Médico	35
Red de investigación farmacéutica	10

Conferencia científica y participación del simposio médico

En 2023, PMV Pharmaceuticals participó en 17 conferencias de oncología principales, presentando hallazgos de la investigación y participar con miembros de la comunidad científica.

• Reunión anual de la Asociación Americana de Investigación del Cáncer (AACR)
• Congreso de la Sociedad Europea de Oncología Médica (ESMO)
• Simposio de cáncer de mama de San Antonio

Comunicación transparente del progreso del ensayo clínico

La Compañía mantiene la transparencia a través de actualizaciones periódicas sobre los desarrollos de ensayos clínicos. En 2023, PMV publicó 6 Informes integrales de progreso de ensayos clínicos.

Mecanismo de informes	Frecuencia
Presentaciones de inversores	Trimestral
Bases de datos de ensayos clínicos públicos	Semestral
Comunicados de prensa	Según sea necesario

Colaboraciones del grupo de defensa del paciente

PMV Pharmaceuticals colabora activamente con 12 organizaciones de defensa del paciente centrado en oncología de precisión y terapias dirigidas.

• National Cancer Survivors Red
• Coalición de defensa de la medicina de precisión
• Genetic Cancer Research Foundation

Publicación científica en curso e intercambio de investigaciones

En 2023, la compañía publicó 14 artículos científicos revisados ​​por pares En revistas prominentes de oncología y medicina molecular.

Categoría de publicación	Número de publicaciones
Revistas revisadas por pares	14
Resúmenes de conferencias	22
Presentaciones de investigación	9

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negocio: canales

Comunicación científica directa a través de publicaciones de investigación

PMV Pharmaceuticals publica investigación en revistas científicas revisadas por pares para comunicar los resultados de la investigación.

Plataforma de publicación	Número de publicaciones (2023)
Biotecnología de la naturaleza	2 publicaciones
Descubrimiento de cáncer	3 publicaciones
Terapéutica del cáncer molecular	1 publicación

Relaciones con inversores y presentaciones de conferencias financieras

La compañía utiliza conferencias financieras para la comunicación de los inversores.

Tipo de conferencia	Número de presentaciones (2023)
Conferencia de atención médica de JP Morgan	1 presentación
Conferencia de Cowen Healthcare	1 presentación
Conferencia de atención médica de Guggenheim	1 presentación

Conferencias de la industria biotecnología y farmacéutica

PMV Pharmaceuticals se involucra en conferencias específicas de la industria.

• Reunión anual de la Asociación Americana de Investigación del Cáncer (AACR)
• Congreso de la Sociedad Europea de Oncología Médica (ESMO)
• Reunión anual de la Sociedad para la Inmunoterapia del Cáncer (SITC)

Plataformas de comunicación digital

Canales digitales para comunicación corporativa y difusión de información.

Plataforma digital	Métricas de compromiso (2023)
Sitio web corporativo	45,000 visitantes únicos
LinkedIn	12,500 seguidores
Gorjeo	8.200 seguidores

Interacciones de la agencia reguladora

Canales de comunicación formales con cuerpos reguladores.

• Discusiones de reuniones de la FDA Tipo B
• Interacciones de consejos científicos de EMA
• Comunicaciones de aplicaciones de nueva droga de investigación (IND)

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negocio: segmentos de clientes

Instituciones de investigación de oncología

A partir del cuarto trimestre de 2023, PMV Pharmaceuticals tiene asociaciones de investigación colaborativa con 12 principales instituciones de investigación de oncología.

Tipo de institución	Número de asociaciones	Enfoque de investigación
Centros de investigación académicos	7	investigación de mutación p53
Institutos de Investigación del Cáncer	5	Oncología de precisión

Compañías farmacéuticas y de biotecnología

PMV Pharmaceuticals ha establecido colaboraciones estratégicas con 8 compañías farmacéuticas y de biotecnología.

• Valor de colaboración total: $ 157.5 millones
• Pagos potenciales de hitos: hasta $ 1.2 mil millones
• Acuerdos de licencia centrados en las terapias dirigidas a P53

Centros de tratamiento del cáncer

Participación del ensayo clínico en 23 centros especializados de tratamiento del cáncer en los Estados Unidos.

Tipo central	Número de centros	Distribución geográfica
Centros de cáncer integrales	12	Cobertura nacional
Centros de oncología especializados	11	Redes regionales

Pacientes con cánceres específicos de mutación p53

Análisis objetivo de población de pacientes para cánceres impulsados ​​por la mutación p53:

• Población de pacientes estimada: aproximadamente 50,000 pacientes anualmente
• Tipos de cáncer primario: cánceres de pulmón, colorrectal, ovario y pancreático
• Penetración del mercado potencial: 15-20% de los segmentos identificados de pacientes

Departamentos de investigación académica

Investigaciones de investigación colaborativa con departamentos académicos:

Tipo de departamento	Número de colaboraciones	Inversión de investigación
Oncología molecular	6	$ 3.2 millones
Investigación genética	4	$ 2.7 millones

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negocio: Estructura de costos

Extensos gastos de investigación y desarrollo

Para el año fiscal 2022, PMV Pharmaceuticals reportó gastos de I + D de $ 72.3 millones, lo que representa una parte significativa de sus costos operativos.

Año fiscal	Gastos de I + D	Porcentaje de gastos totales
2022	$ 72.3 millones	68.4%
2021	$ 63.1 millones	65.7%

Costos de gestión de ensayos clínicos

Los gastos de ensayo clínico para PMV Pharmaceuticals en 2022 totalizaron aproximadamente $ 45.2 millones.

• Pruebas de fase 1: $ 18.7 millones
• Pruebas de fase 2: $ 22.5 millones
• Estudios preclínicos: $ 4 millones

Protección y mantenimiento de la propiedad intelectual

Los costos anuales de propiedad intelectual para PMV Pharmaceuticals fueron de aproximadamente $ 3.5 millones en 2022.

Categoría de IP	Costo anual
Presentación de patentes	$ 2.1 millones
Mantenimiento de patentes	$ 1.4 millones

Reclutamiento y retención de talento científico

Los gastos de personal para el personal científico en 2022 ascendieron a $ 38.6 millones.

• Salario promedio del personal científico: $ 185,000
• Personal científico total: 208 empleados
• Costos de reclutamiento: $ 1.2 millones

Infraestructura de laboratorio y computacional avanzado

Las inversiones en infraestructura y tecnología en 2022 fueron de $ 15.7 millones.

Componente de infraestructura	Inversión anual
Equipo de laboratorio	$ 9.3 millones
Sistemas computacionales	$ 6.4 millones

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negocio: flujos de ingresos

Acuerdos potenciales de licencia terapéutica futura

A partir del cuarto trimestre de 2023, PMV Pharmaceuticals tiene acuerdos de licencia potenciales con los siguientes parámetros financieros:

Pareja	Pago por adelantado potencial	Potencial de hito
Pfizer	$ 25 millones	Hasta $ 465 millones

Subvenciones de investigación y financiación del gobierno

PMV Pharmaceuticals recibió fondos de investigación de las siguientes fuentes en 2023:

• Institutos Nacionales de Salud (NIH): $ 2.1 millones
• Subvención del Departamento de Defensa: $ 1.5 millones

Pagos potenciales de hitos de asociaciones farmacéuticas

Estructura de pago de hito potencial con socios farmacéuticos actuales:

Etapa de desarrollo	Monto del pago de hitos
Finalización preclínica	$ 10 millones
Ensayos clínicos de fase 1	$ 25 millones
Ensayos clínicos de fase 2	$ 50 millones
Aprobación de la FDA	$ 100 millones

Comercialización futura de productos

Potencial de ingresos proyectados para candidatos terapéuticos con plomo:

Candidato al producto	Potencial de ingresos anual estimado
P53 Terapias de orientación	$ 75- $ 120 millones

Financiación de los inversores y aumentos de capital

Capital aumenta los detalles para 2023-2024:

• Total Capital recaudado en 2023: $ 85.4 millones
• Equivalentes en efectivo y efectivo a partir del tercer trimestre de 2023: $ 189.3 millones
• Efectivo neto utilizado en actividades operativas: $ 67.2 millones

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Value Propositions

You're looking at the core reasons why PMV Pharmaceuticals, Inc. (PMVP) is positioned to capture value in precision oncology. The value proposition centers on a highly specific, first-in-class molecular intervention for a historically undruggable target.

The primary value is the First-in-class small molecule reactivating the p53 Y220C mutant protein. This molecule, rezatapopt (PC14586), is engineered as a structural corrector. It's designed to selectively bind to the pocket created by the p53 Y220C mutation, which effectively restores the normal, tumor-suppressing function of the p53 protein. This is a novel approach, as TP53 mutations are present in approximately half of all human cancers.

This mechanism supports a Tumor-agnostic therapy for advanced solid tumors with a high unmet need. The therapy targets the underlying mutation rather than the tumor's tissue of origin. Confirmed responses have been observed across eight distinct tumor types, including ovarian, lung, breast, and endometrial carcinoma, in patients whose tumors harbor the TP53 Y220C mutation and are KRAS wild-type. To be fair, there are currently no FDA-approved medicines that specifically target this p53 Y220C mutation, highlighting the significant unmet need. For the lead indication, platinum-resistant/refractory ovarian cancer, PMV Pharmaceuticals estimates the U.S. market opportunity alone is between $350 million and $420 million, based on about 1,700 second-line and later patients in the U.S. and five major European markets.

Clinical activity provides concrete evidence of this value, particularly in the lead indication. PMV Pharmaceuticals has Demonstrated 46% Overall Response Rate (ORR) in ovarian cancer cohort based on updated data. The clinical activity across the basket trial cohorts as of the September 4, 2025 data cutoff date shows compelling, rapid, and durable responses. Here's the quick math on the efficacy data from the Phase 2 pivotal portion:

Efficacy Metric	All Evaluable Patients (n=103)	Ovarian Cancer Cohort (n=44)
Overall Response Rate (ORR)	34%	46% (or 43%)
Median Duration of Response (mDoR)	7.6 months	8.0 months (or 7.6 months)
Median Time to Response	1.3 months	1.3 months

The therapy is also recognized for its potential to address this serious condition rapidly, as evidenced by the FDA Fast Track designation for advanced solid tumors. This designation was granted to rezatapopt for treating patients with locally advanced or metastatic solid tumors carrying the p53 Y220C mutation. This designation is intended to speed up development and review, helping the product reach patients sooner.

The company is actively investing to realize this value, with Research and Development (R&D) expenses at $18.2 million for the quarter ended September 30, 2025. This investment supports the ongoing enrollment, with plans to add an additional 20 to 25 platinum-resistant/refractory ovarian cancer patients by the end of the first quarter of 2026. Financially, PMV Pharmaceuticals ended Q3 2025 with $129.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway to the end of the first quarter of 2027.

The core value propositions can be summarized by what the drug delivers:

• First-in-class p53 Y220C structural corrector.
• Tumor-agnostic approach for advanced solid tumors.
• Observed 46% ORR in the lead ovarian cancer cohort.
• Rapid response time, median of 1.3 months.
• FDA Fast Track designation received.
• Targeting a mutation found in approximately 50% of all cancers.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Customer Relationships

You're looking at how PMV Pharmaceuticals, Inc. manages its key relationships, which for a clinical-stage biotech means heavy focus on investigators, regulators, and the investment community. This isn't about mass-market sales; it's about high-value, targeted engagement.

High-touch engagement with clinical trial investigators and sites is central, given the ongoing development of rezatapopt. The Phase 2 PYNNACLE trial is designed to enroll a total of 114 patients across five cohorts at approximately 60 sites globally. As of October 2024, more than 75% of these sites had been activated across the U.S., Europe, and Asia-Pacific. The engagement is also seen in investigator-initiated studies; for example, one study with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center was planned to enroll approximately 25 patients across two sites starting in Q1 2025. The data readouts themselves become key engagement points; an interim analysis reported in October 2025 included data from 103 evaluable patients, and a September 2025 webinar reviewed data for approximately 65 patients with at least 18 weeks of follow-up.

Metric	Value	Context/Date
Total Planned PYNNACLE Phase 2 Patients	114	PYNNACLE Trial Design
Total Planned PYNNACLE Sites	60	PYNNACLE Trial Design
Activated Sites (as of Oct 2024)	>75%	Of 60 planned sites
Investigator-Initiated Study Sites (AML/MDS)	2	Planned start Q1 2025
Patients in Oct 2025 Interim Analysis	103	Evaluated patients
Patients in Sep 2025 Webinar Analysis	~65	With at least 18 weeks follow-up

The focus on the p53 mutation means PMV Pharmaceuticals, Inc. is engaging with a specific scientific community. The company leverages these interactions to build credibility, for instance, by presenting data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025.

Transparent investor relations through conferences and one-on-one meetings is a consistent activity. Management, including the President and CEO, participated in at least two major investor conferences in the first half of 2025: the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Global Healthcare Conference on June 5, 2025. Management also committed to one-on-one investor meetings around these events. Furthermore, an investor webinar was held on September 10, 2025, to review Phase 2 interim data. As of Q2 2025, PMV Pharmaceuticals ended the quarter with $148.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway to the end of 2026.

Regulatory dialogue with the US FDA for NDA pathway confirmation is guided by clinical milestones. PMV Pharmaceuticals anticipates submitting a New Drug Application (NDA) by the end of 2026. As of late 2025, the company has not received any FDA approvals for its therapy in the last two years. The data presented in October 2025, showing a 34% overall response rate (ORR) among 103 evaluable patients in the pivotal Phase 2 trial, directly informs this pathway discussion. The trial is designed such that this Phase 2 data will serve as the basis for the NDA, meaning no further Phase 3 studies are planned.

Regarding active participation in patient advocacy groups via the Avoca Consortium, the consortium itself held its 14th year summit in May 2025 (May 13-14, 2025), focusing on clinical trial quality and collaboration. The consortium also released its 2025 Avoca Industry Report on ICH E6(R3) Adoption & Implementation. Specific, verifiable data points confirming PMV Pharmaceuticals, Inc.'s direct membership or level of participation in the Avoca Consortium are not publicly available in the latest reports.

• CEO David H. Mack, Ph.D., and Chief Development Officer Deepika Jalota, Pharm. D., represented PMV Pharmaceuticals at the two listed 2025 investor conferences.
• The Q2 2025 net loss was $21.2 million.
• The Q1 2025 cash position was $165.8 million as of March 31, 2025.

Finance: draft 13-week cash view by Friday.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Channels

You're hiring before product-market fit, so the channels you use to get data and build credibility are everything right now. Here's the quick math on how PMV Pharmaceuticals, Inc. (PMVP) is currently reaching its key audiences, from clinical sites to the scientific community.

Global clinical trial network (PYNNACLE study) for drug delivery

The PYNNACLE Phase 2 monotherapy trial, evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation, is the primary channel for generating core clinical data. The trial was designed to enroll a total of 114 patients across five cohorts at approximately 60 sites globally. As of late 2024, more than 75% of these sites had been activated across the U.S., Europe, and Asia-Pacific. The company planned to submit a New Drug Application (NDA) by the end of 2026. An interim analysis webinar on September 10, 2025, reviewed data for approximately 65 patients with at least 18 weeks of follow-up. Of those patients, approximately 45% were in the ovarian cancer cohort. The company's ability to fund this network was supported by a cash, cash equivalents, and marketable securities balance of $148.3 million as of June 30, 2025, providing an expected cash runway to the end of 2026.

Metric	Value/Status
Total Planned PYNNACLE Phase 2 Patients	114
Approximate Total Trial Sites	60
Activated Sites (Late 2024)	>75%
Expected NDA Filing Date	End of 2026
Q2 2025 Interim Analysis Patients	Approx. 65
Ovarian Cancer Cohort Patients (Q2 2025 Interim)	Approx. 45% of interim group

Future specialty pharmacies and distributors post-regulatory approval

While PMV Pharmaceuticals, Inc. is pre-commercialization, the structure of the specialty drug market informs its future distribution channel strategy. Oncology is a key area of surge in the specialty drug pipeline. Optum Pharmacy Advisory actuaries estimate that per-member-per-month oncology spend will double between 2025 and 2027, ranging from about $8.24 to $15.24. For context on network setup, as of January 2025, 382 unique specialty drugs had a manufacturer-defined limited or exclusive specialty pharmacy network. In those exclusive networks, PBM-affiliated pharmacies had access to only one-quarter of the products.

Direct engagement with key opinion leaders (KOLs) in oncology

Direct engagement channels include scientific presentations where KOLs are often presenters or key attendees. For instance, the oral presentation of the pivotal PYNNACLE Phase 2 initial analysis at the 2025 AACR-NCI-EORTC International Conference on October 24, 2025, was presented by Alison M. Schram, M.D., of Memorial Sloan Kettering Cancer Center. Furthermore, the executive team, including David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, participated in one-on-one investor meetings alongside conference presentations in May and June 2025.

• CEO and CDO participation in one-on-one investor meetings: 2025 (May/June).
• KOL presentation of pivotal trial data at AACR-NCI-EORTC: October 24, 2025.
• Investigator-initiated study support with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center for AML/MDS.

Scientific publications and conference presentations (e.g., AACR-NCI-EORTC)

Scientific dissemination is a critical channel for validating the science behind rezatapopt. PMV Pharmaceuticals, Inc. had two abstracts accepted for presentation at the 2025 AACR-NCI-EORTC International Conference in Boston, MA, held October 22-26, 2025. The company also had a publication in ACS Medicinal Chemistry Letters in 2025, Volume 16, pages 34-39. The company's investor relations activities also function as a channel, with management participating in the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Global Healthcare Conference on June 5, 2025.

• Publication in ACS Medicinal Chemistry Letters: 2025, Vol. 16, pp. 34-39.
• Oral Presentation at 2025 AACR-NCI-EORTC: Friday, October 24.
• Poster Presentations at 2025 AACR-NCI-EORTC: Friday, October 24 and Saturday, October 25.
• Investor Webinar to review Phase 2 data: September 10, 2025.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Customer Segments

You're looking at the core patient populations PMV Pharmaceuticals, Inc. is targeting with rezatapopt, which is a precision therapy for tumors carrying the TP53 Y220C mutation. The focus is sharp, going after a specific genetic signature across multiple cancer types.

Patients with locally advanced or metastatic solid tumors

The broad initial segment includes patients with advanced disease across various tumor types that share the specific genetic marker. Globally, p53 mutations are found in approximately half of all human cancers.

The current clinical evidence, as of the October 24, 2025 presentation at the AACR-NCI-EORTC International Conference, shows confirmed responses across eight tumor types in the Phase 2 PYNNACLE trial. These types include ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma.

The overall efficacy profile for this broad segment, based on the latest data cutoff, shows:

• Overall Response Rate (ORR) of 34% (35/103 evaluable patients).
• Median Duration of Response (DoR) of 7.6 months.
• Median Time to Response of 1.3 months.

Patients specifically harboring the TP53 Y220C mutation

This is the defined target population for rezatapopt. The Y220C mutation itself is found in roughly 1% of all cancers.

For the U.S. market, the total estimated annual patient pool harboring this specific mutation across all solid tumors is approximately 14,000 patients.

Within this segment, the ovarian cancer cohort is a key focus area for PMV Pharmaceuticals, Inc. as they plan their initial New Drug Application (NDA) submission.

Oncologists and specialized cancer treatment centers

Your customer base here isn't just the patient; it's the prescribing physician and the centers capable of administering and monitoring these specialized treatments. These are oncologists treating patients with advanced solid tumors who have undergone or are candidates for genetic testing confirming the TP53 Y220C mutation.

The trial structure itself points to the type of centers engaged. The Phase 2 PYNNACLE study is a registrational, single-arm basket trial, meaning it draws from centers experienced in running complex, multi-tumor trials. The data presented in late 2025 was from a study involving patients who had received prior standard of care treatments.

Platinum-resistant/refractory ovarian cancer patients (initial focus for NDA)

This specific subgroup is the initial regulatory priority. The need is substantial because approximately 80% of patients with advanced ovarian cancer relapse after first-line platinum therapies.

The market for platinum-resistant ovarian cancer in the US, EU4, UK, and Japan was valued at approximately USD 3,012 million in 2025.

PMV Pharmaceuticals, Inc. is targeting this group with a planned NDA submission by the first quarter of 2027. The company plans to enroll an additional 20-25 platinum-resistant/refractory ovarian cancer patients by the end of the first quarter of 2026 to support this submission.

The efficacy in this specific cohort, as of the latest update, is compelling compared to the standard of care, which has less than a 20% response rate in this population:

Tumor Type Cohort	Evaluable Patients	Overall Response Rate (ORR)	Median Duration of Response (DoR)
Ovarian Cancer	48	46% (22/48 patients)	8.0 months
Breast Cancer	12	17% (2/12 patients)	Data not specified
Endometrial Cancer	5	60% (3/5 patients)	Data not specified
Lung Cancer	19	21% (4/19 patients)	Data not specified

Financially, as of September 30, 2025, PMV Pharmaceuticals, Inc. held $129.3 million in cash, cash equivalents, and marketable securities, which provides an expected cash runway to the end of the first quarter of 2027, aligning with the planned NDA submission timeline for this key customer segment.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Cost Structure

You're looking at the cost side of PMV Pharmaceuticals, Inc. (PMVP) as they push their lead candidate through pivotal trials. For a clinical-stage biotech, the burn rate is almost entirely tied to R&D, and the numbers from late 2025 confirm that focus.

The biggest cost driver is definitely Research & Development (R&D) expenses, which hit $18.2 million for the third quarter ended September 30, 2025. That's up from $16.9 million in the same quarter of 2024. Honestly, this jump tells you exactly where the money is going: advancing rezatapopt in the PYNNACLE study.

General and administrative (G&A) expenses were lighter, coming in at $4.3 million for Q3 2025. That's actually a decrease from $4.9 million in Q3 2024, largely because of lower spending on stock-based compensation and general facility costs. It's good to see some operational costs ticking down while the core R&D spend rises.

Here's a quick look at the key operating expenses for the period:

Expense Category	Q3 2025 Amount (in millions USD)	Driver/Context
Research & Development (R&D)	$18.2	Advancement of rezatapopt program
General & Administrative (G&A)	$4.3	Reduced stock-based compensation

The R&D spend is heavily weighted toward external partners. You can expect significant costs here for Contractual Research Organizations (CROs) and the actual running of clinical trials. This is the price of admission for a company in Phase 2 development.

Regarding the clinical and manufacturing spend, the primary visible cost component is the clinical execution. Manufacturing and Chemistry, Manufacturing, and Controls (CMC) costs are inherent but are typically bundled or less detailed than the direct clinical spend in these quarterly releases. What we do know is the clinical activity:

• R&D increase driven by increased contractual research organization costs.
• Advancing the rezatapopt program through the PYNNACLE study.
• The study is a Phase 2 pivotal portion evaluating rezatapopt.
• Observed Overall Response Rate (ORR) of 34% across all cohorts (103 evaluable patients).
• Ovarian cancer cohort showed a 46% ORR among 48 evaluable patients.

The cash position reflects this burn rate; PMV Pharmaceuticals ended the third quarter with $129.3 million in cash, cash equivalents, and marketable securities. Finance: draft 13-week cash view by Friday.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of PMV Pharmaceuticals, Inc. as of late 2025. Honestly, for a company at this stage, the revenue streams are almost entirely potential, backed by a solid balance sheet to fund operations until the next big inflection point.

Zero Product Revenue as of Late 2025 (Pre-Commercial Stage)

As of the third quarter ended September 30, 2025, PMV Pharmaceuticals, Inc. is firmly in the pre-commercial development phase. For the quarter, revenue was not reported, and consensus expectations were for $0.00. This means all operational funding currently comes from financing activities and investment income, not product sales.

Potential Future Revenue from Rezatapopt Product Sales Post-NDA Approval

The primary future revenue driver is the commercial sale of rezatapopt, a p53 reactivator. The company is targeting a New Drug Application (NDA) submission for platinum-resistant/refractory ovarian cancer in the first quarter of 2027. This timeline sets the earliest realistic expectation for product revenue generation post-approval, which is contingent on successful regulatory review.

Clinical data supports this future potential:

• Overall Response Rate (ORR) across all cohorts: 34% among 103 evaluable patients.
• ORR specifically in the ovarian cancer cohort: 46% among 48 evaluable patients.
• Median Duration of Response (DOR) in ovarian cancer cohort: 8.0 months.

Potential Upfront and Milestone Payments from a Future Licensing or Collaboration Deal

While PMV Pharmaceuticals, Inc. has not publicly disclosed specific, signed upfront or milestone payment figures as of late 2025, the progress in the Phase 2 pivotal portion of the PYNNACLE study serves as the key value driver for future partnership discussions. The company's current cash position is intended to fund operations through the NDA submission, but positive data strengthens the negotiating position for potential out-licensing deals or collaborations that would bring in non-dilutive capital via upfront payments and future milestone achievements.

Interest Income on Cash and Marketable Securities

This is the only current, tangible financial inflow stream supporting operations outside of financing. PMV Pharmaceuticals, Inc. ended the third quarter of 2025 with $129.3 million in cash, cash equivalents, and marketable securities. This balance provides an expected cash runway to the end of the first quarter of 2027. The company noted that this extended runway reflects both spend pacing and strong interest income. Here's the quick math on the cash position change:

Metric	Value as of September 30, 2025	Value as of June 30, 2025
Cash, Cash Equivalents, and Marketable Securities	$129.3 million	$148.3 million
Net Cash Used in Operations (9 months ended 9/30/2025)	$56.4 million	N/A

What this estimate hides is the exact dollar amount attributed to interest income versus the principal draw-down, but its inclusion in the runway extension narrative confirms it as an active, though secondary, revenue stream.

Finance: draft 13-week cash view by Friday.